Industrial Transformation Training Centres - Grant ID: IC170100016
Funder
Australian Research Council
Funding Amount
$3,123,492.00
Summary
ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therap ....ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therapeutics. The use of an individual patient’s cellular and molecular research findings will ultimately enable personalised diagnostic and therapeutic decisions.Read moreRead less
We have discovered a single tumour factor which causes cancer cachexia, a wasting condition that is one of the worst complications of malignancy, for which there is no current effective treatment. We have developed antibodies which effectively block this condition in preclinical models and have produced human/humanised version of this. This application is to characterise these human antibodies to allow us proceed to clinical trials.
Alpha-particles linked to recombinant antibodies targeting tumour cells have potential to effectively treat tumours while minimising normal tissue side effects. We will explore a novel alpha-particle therapy approach to solid tumours, by delivering 225Ac directly into tumour cells, or into cells that support the tumour (microenvironment). This approach will hopefully result in development of a new approach to treatment of cancers that are resistant to conventional therapies.
Melanotransferrin: A “Missing Link” And A Novel Pharmacological Target For Treatment
Funder
National Health and Medical Research Council
Funding Amount
$613,848.00
Summary
Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.
Generating multi-component scaffolding to influence the differentiation of embryonic stem cells. Nervous system diseases are debilitating and will develop in over 50 per cent of people at some time in their life. This project will develop strategies so that stem cells can be utilised to encourage brain repair for the treatment of Parkinson's disease. The technology developed will also be of benefit for the treatment of other nervous system disorders.
Special Research Initiatives - Grant ID: SR1101002
Funder
Australian Research Council
Funding Amount
$21,000,000.00
Summary
Stem Cells Australia. Despite progress in stem cell research, scientists do not understand how stem cells “decide” what to become. Stem Cells Australia will draw upon strengths within Australia’s premier stem cell research universities and institutes. This collaboration between leading bioengineering, nanotechnology, stem cell and advanced molecular analysis experts, will fast-track efforts to deliver a fundamental understanding of the mechanisms of stem cell regulation and differentiation, and ....Stem Cells Australia. Despite progress in stem cell research, scientists do not understand how stem cells “decide” what to become. Stem Cells Australia will draw upon strengths within Australia’s premier stem cell research universities and institutes. This collaboration between leading bioengineering, nanotechnology, stem cell and advanced molecular analysis experts, will fast-track efforts to deliver a fundamental understanding of the mechanisms of stem cell regulation and differentiation, and the ability to control and influence this process. Stem Cells Australia will deliver new methods for stem cell propagation and manipulation, new translational technologies for therapeutic applications, and will prepare Australia’s future stem cell scientific leaders.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE180100775
Funder
Australian Research Council
Funding Amount
$368,446.00
Summary
Using nanostructured scaffolds to understand and engineer neuronal circuits. This project aims to understand the formation of neuronal circuits in the brain. While the role of biochemical features in the brain is well understood, it is not clear how the biophysical properties of the brain affect circuit formation. The outcomes of this project will improve our understanding of neuronal circuit formation as well as provide design rules for creating scaffolds to repair neuronal circuits after brain ....Using nanostructured scaffolds to understand and engineer neuronal circuits. This project aims to understand the formation of neuronal circuits in the brain. While the role of biochemical features in the brain is well understood, it is not clear how the biophysical properties of the brain affect circuit formation. The outcomes of this project will improve our understanding of neuronal circuit formation as well as provide design rules for creating scaffolds to repair neuronal circuits after brain damage. This project will integrate Australia’s strengths in nanotechnology and neurosciences, bringing Australian research at the forefront of neural engineering.Read moreRead less
Griseofulvin, A Novel Host-directed Antimalarial Drug
Funder
National Health and Medical Research Council
Funding Amount
$461,551.00
Summary
This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.
Industrial Transformation Training Centres - Grant ID: IC190100026
Funder
Australian Research Council
Funding Amount
$4,969,663.00
Summary
ARC Training Centre for Cell and Tissue Engineering Technologies. The ARC Training Centre for Cell and Tissue Engineering Technologies aims to provide training to create a highly skilled workforce for the tissue engineering and regenerative medicine sector and to enhance research performance and innovation in Australia through fundamental and applied research carried out in industry-led PhD projects. The research aims to address major aspects of the manufacturing and commercialisation pathway an ....ARC Training Centre for Cell and Tissue Engineering Technologies. The ARC Training Centre for Cell and Tissue Engineering Technologies aims to provide training to create a highly skilled workforce for the tissue engineering and regenerative medicine sector and to enhance research performance and innovation in Australia through fundamental and applied research carried out in industry-led PhD projects. The research aims to address major aspects of the manufacturing and commercialisation pathway and barriers faced by the sector, namely improving process efficiencies, enabling early-stage scale-up (cell/tissue) and development of the sector's supply chain. The knowledge created and research undertaken would help to accelerate commercialisation in regenerative medicine, tissue engineering and cell therapies.Read moreRead less